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tions typically involve continuous bladder irrigation (CBI), fre-
quent platelet transfusions, and medications for symptom control.
Because effective management for HC has not been established,
other alternatives, such as the use of activated factor VII and
hyperbaric oxygen therapy, are being examined. Hyperbaric oxy-
gen therapy provides a noninvasive approach to the management
and resolution of this problematic complication. A case study will
be presented to demonstrate the necessity of further understanding
of these approaches for the treatment of HC.
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THE NURSE’S ROLE AS COORDINATOR IN THE SAFE AND EFFECTIVE
MANAGEMENT OF PATIENTS WITH COMORBIDITIES UNDERGOING AL-
LOGENEIC STEM CELL TRANSPLANTATION
Ramos, C., Cook, L., Shelburne, N., Bevans, M. National Institutes of
Health, Bethesda, MD.
Allogeneic stem cell transplantation (SCT) is an intense treat-
ment offering a potential cure for leukemia. Transplantation-re-
lated complications (TRCs), in addition to the effects of the un-
derlying disease, are common during transplantation. To avoid
secondary complications such as falls, intense monitoring by the
patient, family, and health care team are required. Blindness, a rare
but serious toxicity of leukemia and associated treatments, can
further complicate the patient’s experience during transplantation
and put him or her at increased risk for injury.
Before admission of a leukemia patient with new-onset blindness,
a team of clinical research oncology nurses recognized the unique
degree of personal, emotional, and physical dependence of this
high-risk patient. This high level of dependence required a com-
mitment by the patient, family, and health care team beyond that
normally expected. This generated a need for a unique education
plan related to the environment, activities of daily living, and
communication approaches. To develop this plan and ensure a safe
environment, the clinical research nurses used a collaborative care
model to involve the health care team. An important element in
this model was the inclusion of all disciplines involved in patient
care and community resources.
The purpose of this project is to share a collaborative care model
that improves the management of allogeneic SCT patients with
comorbidities such as blindness. The success of this model was
based on the inclusion of supportive care personnel normally
outside the transplantation team. This presentation will outline the
nurse’s role as coordinator of an expanded multidisciplinary team
in managing unique and complex patients undergoing SCT. These
include achievement of functional independence, injury preven-
tion, and improved psychological well-being for the patient and
family.
The oncology nurse is in a key position to identify the risk level
of unique patients undergoing allogeneic SCT and bring together
multiple resources, in the hospital and community, to support the
patient and family. This collaborative care model demonstrates the
effectiveness of the oncology nurses’ role as a coordinator of the
multidisciplinary team in achieving high-quality patient and family
care. This model can be applied to other high-risk cancer patients
that may be at increased risk of injury due to other comorbid
conditions as they present for SCT.
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UNDERSTANDING VENO-OCCLUSIVE DISEASE IN THE BLOOD AND
MARROW TRANSPLANTATION POPULATION: THE NURSE’S ROLE
Brandert, M., Ippoliti, C. University of Texas M.D. Anderson Cancer
Center, Houston, TX.
Veno-occlusive disease (VOD) is a serious, often fatal complica-
tion of blood and marrow transplantation (BMT). It has been
reported that VOD is the third-leading cause of transplantation-
related mortality in allogeneic patients, after graft-versus-host dis-
ease and infection. Research indicates the reported incidence of
VOD may be as high as 54%. Onset of symptoms usually occurs
within the ﬁrst 30 days posttransplantation; however, reports of
VOD occurring after day 30 have also been documented. The
diagnosis of VOD is made after other potential complications of
transplantation are ruled out. Clinical features may include ﬂuid
retention, weight gain, ascites, right upper quadrant pain, and
jaundice. Once a diagnosis of VOD is made, aggressive treatment
is necessary. Therapeutic goals are aimed at maintaining renal
perfusion and intravascular volume while limiting extravascular
ﬂuid accumulation, and inhibiting the coagulation cascade.
New therapeutic approaches to the treatment of VOD continue to
be examined. Studies using the drug deﬁbrotide have shown it to be
highly efﬁcacious, while minimizing toxicity. A case study will be
presented that reviews the use of deﬁbrotide on a matched unrelated
donor transplantation receipient diagnosed with VOD. The diagnosis
can have a major impact on the treatment and care of these patients.
Knowledge of the risk factors, pathophysiology, and clinical features
of this syndrome can assist nurses with early detection, symptom
management, supportive care, and patient and family education.
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THE EXPERIENCE OF INTENSIVE CARE UNIT FOR HEMATO-ONCOLOGY
PATIENTS
Kim, H.J., Youn, J.H., Shim, S.M., Hong, E.Y., Kim, K.S., Ban, J.Y.,
Han, S.S., Cho, H.S., Song, B.E. St. Mary’s Hospital, Catholic HSCT
Center, Seoul, Korea.
We established in intensive care unit for hemato-oncology pa-
tient since 1999. In fact, we have concerned about transfer inten-
sive care unit in spite of leukopenic status the reason why infection.
We reviewed the medical records of 310 patients, there were the
data, initial diagnosis, cause of admission and reason to ICU,
admission duration, need for mechanical ventilation and cause of
death, from January 2003 to April 2004 for 13months to identify
efﬁcacy of intensive care and further direction. The mean age was
38.9 years old, 174(56%) of them were men and 136 of them were
women. The distribution of disease was orderly AML (41.94%),
ALL 50(16.13%), CML 27(8.71%), SAA 21(6.77%), MDS
17(5.48%) and so on. The type of treatment was Chemo-therapy
102(32.9%), Post HSCT 97(31.3%). The admission duration was
8.19 days, there was no signiﬁcant between HSCT and chemo-
therapy. However, comparably HSCT group was higher than
conservative care group.
The reason for transfer to Hematology ICU was interstitial
pneumonia 88(28.38%), sepsis 76(24.52%), organ failure
61(19.68%). The mechanical ventilator care group of them was
138(44.5%). The reason of them was interstitial pneumonia
48(34.78%), sepsis 27(19.57%), organ failure 24(17.39%). The
mortality of ventilator care group was 111(80.43%, P
One hundred four patients (33.55%) of subject were improved.
Yet, 160(51.61%) were died and 46(14.84%) were hopeless dis-
charged. The direct and contributing cause of death was Multi-
organ failure 91(56.88%), sepsis 33(20.63%). The mortality of
HSCT group was 66(68%) and chemotherapy group was 49(48%).
The mortality of HSCT group was relatively higher than chemo-
therapy group. Ninety-one of Non-ventilator group were im-
proved the meaning was better than ventilator care group. There
were different of mortality compare with between Mechanical
ventilator group 111(69.37%) and Non-ventilator care group
49(30.63%).
In conclusion, we suggest that a classiﬁcation tool should be
developed to predict prognostic factor of speciﬁc hemato-oncolgy
intensive care.
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A COMPETENCY-BASED ORIENTATION TOOL FOR INITIAL ORIENTA-
TION TO THE CARE OF BLOOD AND MARROW TRANSPLANTATION
PATIENTS
Grifﬁn, J.M., Brauning, N., Kehoe, B., Poonoosamy, S. Jewish Hospital,
Cincinnati, OH.
Blood and marrow transplantation (BMT) nursing requires a
speciﬁc set of competencies to provide effective care to BMT
patients. The development of a competency-based orientation tool
(CBO) speciﬁc to BMT is one strategy to standardize the orien-
tation of nurses new to BMT. A BMT-speciﬁc CBO facilitates the
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